Nov 21, 2024 7:00am EST Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Nov 13, 2024 7:15am EST Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Nov 11, 2024 7:00am EST Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Oct 28, 2024 7:03am EDT Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Oct 16, 2024 4:35pm EDT Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
Oct 14, 2024 7:03am EDT Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
Oct 09, 2024 7:03am EDT Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
Sep 24, 2024 7:03am EDT Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Sep 16, 2024 7:03am EDT Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
Sep 05, 2024 7:03am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
